A patient with progressive, unresectable well-differentiated pancreatic NET has negative somatostatin-receptor imaging and HbA1c 91 mmol/mol despite

Question

A patient with progressive, unresectable well-differentiated pancreatic NET has negative somatostatin-receptor imaging and HbA1c 91 mmol/mol despite optimisation of diabetes therapy. Which NICE-approved targeted option is the more rational choice if cytoreduction is not urgently required?

Accepted Answer

Sunitinib with glucose monitoring and standard toxicity surveillance

Answer

Everolimus with unchanged diabetes therapy and routine glucose monitoring

Answer

Lutetium-177 oxodotreotide after repeating receptor imaging in three months

Answer

Capecitabine-temozolomide for elective disease-control therapy after MDT discussion

Answer

Octreotide dose escalation with radiological reassessment after three cycles

Pancreatic NET — SCE Medical Oncology MCQ

A patient with progressive, unresectable well-differentiated pancreatic NET has negative somatostatin-receptor imaging and HbA1c 91 mmol/mol despite optimisation of diabetes therapy. Which NICE-approved targeted option is the more rational choice if cytoreduction is not urgently required?